Germany’s Merck KGaA has partnered with techbio company Caris Discovery in a $1.4 billion alliance that will apply artificial intelligence to the design of antibody-drug c
Antibody developer Genmab has made a play to boost its expertise in the scalding hot area of antibody-drug conjugates (ADCs), agreeing a $1.8 billion deal to acquire Profo
Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.
Munich-based antibody-drug conjugate (ADC) specialist Tubulis has completed a sizeable Series B2 financing that shows sustained investor appetite for the ADC category, par
The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan i
The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC